The Rx rate of Lipitor and Plavix is high

The patent expiry drug is running backward

Outpatient Rx performance analysis by 2019, Lipitor leads for two consecutive years

Original drugs such as Plavix, Crestor and Aricept are on the rise

Gliatamin and Rosuzet among domestic development products continue their sweeping upturn

Last year, the strength of patent expiration drugs stood out in the top domestic outpatient drug market.

 

Lipitor, a hyperlipidemia treatment drug, continued to rise and remained No.1 in the prescription market for two consecutive years.

 

The antithrombotic drug Plavix has grown by about 50% in five years.

 

'Twynsta', 'Crestor', and 'Aricept' also increased the amount of prescriptions despite the generics.

 

Among the products developed by domestic companies, 'Gliatamin' and 'Rosuzet' showed a remarkable progress.

 

Last year, Lipitor took the lead in outpatient Rxs of ₩176.2 billion, according to drug research agency UBIST.

 

It was 8.4% higher than the previous year, winning the Rx market for two consecutive years.

 

In 2017, Gilead's hepatitis B treatment, Viread, ranked first.

 

Outpatient Rx Performance Rank by item in 2019 (Unit: ₩100 million,%, Source: UBIST)

Lipitor is clearly ranked first in the outpatient Rx market with a gap of ₩69.4 billion from the second-largest Viread.

 

Hyperlipidemia drug Lipitor by Pfizer

Lipitor, which was released in Korea in 1999, is exceptional.

 

More than 100 generic products have entered since 2009, and insurance prices have fallen by half compared to before patent expiration.

 

Pfizer recently received a series of large-scale clinical studies on Koreans, engaged in a variety of social contribution activities, and is said to have concentrated on Lipitor.

 

Last year, the prescription market showed the most notable increase in patent expired drugs.

 

.

Sanofi's Plavix last year recorded prescription results of ₩88.9 billion, up 17.3% from the previous year

 

.Rx amount of Plavix increased 28.1% in two years from ₩69.4 billion in 2017

 

.Prescription performance of Plavix has risen by 48.2% in five years from ₩60 billion in 2014

 

.The patent expired in 2007 and has entered more than 120 generics

 

.The accompanying rise in patent expired drugs is a very unusual phenomenon

 

.In general, the market share drops rapidly after the release of drugs such as generics or salt-changed generics

 

.In the domestic market, the market share is increasing

 

.Prescriptions also increased last year, compared to last year's generic competition, including Boehringer Ingelheim's Twynsta, Eisai's Aricept and Novartis' Exforge

 

.Due to the domestic drug price system, original drugs are said to be favorable for market share expansion

 

.In Korea, when generics are released, the drug price of original drugs drops to the previous 70% level

 

.After one year, the price will drop to 53.55% before patent expiration

 

.The upper limit of the generic drug can be up to 59% of the original drug before the patent expires, and after one year, the price goes down to 53.55% like the original

 

.After the patent expiration of new drugs, drug prices were similar to those of generics, and it is analyzed that the prescription of the original drug has increased in the prescription field

 

.It is estimated that the market defense of patent expired drugs is firmly established by strengthening sales activities of domestic pharmaceutical companies

 

.Lipitor is sold jointly by Jeil Pharm, while Plavix and Twynsta are sold by Dong-wha and Yuhan

 

.Domestic patented new drug products such as Crestor (Daewoong), Aricept(Chong Kun Dang), and Harnal(Boryeong) also joined the business

 

.Viread, which ranked No

 

.1 in prescription drugs in 2017, fell outpatient prescriptions at ₩106.4 billion last year, down 30.5% YoY

 

.The gap with leading Lipitors widened sharply due to drug price cuts and a decline in market share

 

.Daewoong Bio's “Gliatamin,” a brain function improving agent of “Choline Alfoscerate”, recorded the most of ₩91.6 billion of outpatient prescriptions last year

 

.It is up 19.5% from ₩76.7 billion in 2018

 

.Chong Kun Dang's “CKD Gliatilin Soft Cap” of the same ingredient also posted a prescription of ₩72.3 billion, up 14.9% from the previous year

 

.Last year, the effectiveness of choline alfoscerate was debated, but it still rose sharply

 

.'Rosuzet', launched by Hanmi in late 2015, recorded ₩77.3 billion, up 36.4% from last year

 

.Rosuzet is a hyperlipidemic complex consisting of Rosuvastatin and Ezetimibe

 

.Hanmi entered the market earlier than its competitors by securing the right to use Ezetimibe from the patent holder MSD and ranks first in the same ingredient market

 

.Hanmi's hypertension complex, Amosartan, was listed at the top of last year with a prescription of ₩74.1 billion

 

.Amosaltan, released in 2009, is a hypertensive complex that combines calcium channel blocker (CCB) 'Amlodipine' and angiotensin II receptor blocker (ARB) 'Losartan'.